Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2024 Aug 8:2024.08.07.24311613.
doi: 10.1101/2024.08.07.24311613.

Genomic ascertainment of CHEK2-related cancer predisposition

Sun Young Kim  1   2 , Jung Kim  1 , Mark Ramos  1 , Jeremy Haley  3 , Diane Smelser  3 , H Shanker Rao  3 , Uyenlinh L Mirshahi  3 ; Geisinger-Regeneron DiscovEHR Collaboration; Barry I Graubard  4 , Hormuzd A Katki  4 , David Carey  3 , Douglas R Stewart  1
Affiliations

Genomic ascertainment of CHEK2-related cancer predisposition

Sun Young Kim et al. medRxiv. .

Abstract

Purpose: There is clear evidence that deleterious germline variants in CHEK2 increases risk for breast and prostate cancers; there is limited or conflicting evidence for other cancers. Genomic ascertainment was used to quantify cancer risk in CHEK2 germline pathogenic variant heterozygotes.

Patients and methods: Germline CHEK2 variants were extracted from two exome-sequenced biobanks linked to the electronic health record: UK Biobank (n= 469,765) and Geisinger MyCode (n=170,503). Variants were classified as per American College of Medical Genetics and Genomics (ACMG)/Association for Molecular Pathology (AMP) criteria. Heterozygotes harbored a CHEK2 pathogenic/likely pathogenic (P/LP) variant; controls harbored benign/likely benign CHEK2 variation or wildtype CHEK2. Tumor phenotype and demographic data were retrieved; to adjust for relatedness, association analysis was performed with SAIGE-GENE+ with Bonferroni correction.

Results: In CHEK2 heterozygotes in both MyCode and UK Biobank, there was a significant excess risk of all cancers tested, including breast cancer (C50; OR=1.54 and 1.84, respectively), male genital organ cancer (C60-C63; OR=1.61 and 1.77 respectively), urinary tract cancer (C64-C68; OR=1.56 and 1.75, respectively) and lymphoid, hematopoietic, and related tissue cancer (C81-C96; OR=1.42 and 2.11, respectively). Compared to controls, age-dependent cancer penetrance in CHEK2 heterozygotes was significantly younger in both cohorts; no significant difference was observed between the penetrance of truncating and missense variants for cancer in either cohort. Overall survival was significantly decreased in CHEK2 heterozygotes in UK Biobank but there was no statistical difference in MyCode.

Conclusion: Using genomic ascertainment in two population-scale cohorts, this investigation quantified the prevalence, penetrance, cancer phenotype and survival in CHEK2 heterozygotes. Tailored treatment options and surveillance strategies to manage those risks are warranted.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Odds ratio for All, PTV and PMV CHEK2 heterozygotes for organ system groupings of cancer ICD codes with a significant excess of risk in MyCode (panel A) and UK Biobank (panel B).
CI: 95% confidence interval; OR: odds ratio; PMV: pathogenic missense variant; PTV: pathogenic truncating variant
Figure 2.
Figure 2.. Odds ratio for All, PTV and PMV CHEK2 heterozygotes for specific cancers in the organ system groupings of cancer ICD codes with a significant excess of risk in MyCode (panel A) and UK Biobank (panel B).
CI: 95% confidence interval; OR: odds ratio; PMV: pathogenic missense variant; PTV: pathogenic truncating variant
Figure 3.
Figure 3.. Penetrance of pathogenic CHEK2 variants for cancer and all-cause mortality in MyCode.
Panel A: Time-to-cancer (penetrance); Panel B: All-cause mortality; Panel C: All-cause mortality for individuals with cancer. PMV: pathogenic missense variant; PTV: pathogenic truncating variant.
Figure 4.
Figure 4.. Penetrance of pathogenic CHEK2 variants for cancer and all-cause mortality in UK Biobank.
Panel A: Time-to-cancer (penetrance); Panel B: All-cause mortality; Panel C: All-cause mortality for individuals with cancer. PMV: pathogenic missense variant; PTV: pathogenic truncating variant
See this image and copyright information in PMC

References

    1. Stolz A, Ertych N, Bastians H: Tumor suppressor CHK2: regulator of DNA damage response and mediator of chromosomal stability. Clin Cancer Res 17:401–5, 2011 - PubMed
    1. Hanson H, Astiazaran-Symonds E, Amendola LM, et al.: Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med 25:100870, 2023 - PMC - PubMed
    1. Dorling L, Carvalho S, Allen J, et al.: Breast cancer risks associated with missense variants in breast cancer susceptibility genes. Genome Med 14:51, 2022 - PMC - PubMed
    1. Wilczewski CM, Obasohan J, Paschall JE, et al.: Genotype first: Clinical genomics research through a reverse phenotyping approach. Am J Hum Genet 110:3–12, 2023 - PMC - PubMed
    1. Bycroft C, Freeman C, Petkova D, et al.: The UK Biobank resource with deep phenotyping and genomic data. Nature 562:203–209, 2018 - PMC - PubMed

Publication types